On 20 March, the 27th China International Food Ingredients China (FIC 2024) commenced in grand style at the National Exhibition and Convention Centre in Shanghai. Making its debut at FIC as China's pioneering domestic HMO leader, Synaura Biotech captured significant attention from numerous attendees.

Synaura Innovation Symposium

That morning, the Synaura Biotech Innovation Symposium brought together experts from diverse fields to share new developments in HMOs within the food sector with attendees.

Mr He Yuanchao, CEO of Meow Factory and innovation specialist, delivered a presentation titled ‘The Path to Innovation in Infant Nutrition in the Era of Precision Feeding’. From a brand marketing perspective, he elaborated on how HMOs can play a pivotal role in precision feeding within the current context of transformation and upgrading in the infant nutrition industry.

Professor Li Chun from Northeast Agricultural University delivered a presentation entitled ‘Research on the Efficacy of Human Milk Oligosaccharides: Gut, Immunity and Allergy’. The presentation provided an in-depth overview from a scientific perspective of research findings concerning the role of HMOs in enhancing gut health, boosting immunity and preventing allergies.

In the ‘Global Application Scan of Human Milk Oligosaccharides (HMOs)’ report, Ms Yao Fei, Head of Application R&D at Synaura Biotech, shared with attendees the current global application landscape and innovative prospects for HMOs across the food, cosmetics and healthcare sectors.

Dr Zhang Hanzhi, Chief Testing Officer at Synaura Biotech, delivered an in-depth presentation on ‘HMO Detection Methods and Analysis of Common Issues’ from a testing perspective. The presentation covered cutting-edge knowledge in HMO detection technology, analysed common challenges encountered in current testing processes, and provided valuable industry insights.

Strategic Cooperation Signing Ceremony

Furthermore, attendees witnessed the signing ceremony for the strategic cooperation between Synaura Biotech (Shanghai) Co., Ltd. and Xi'an Libang Clinical Nutrition Co., Ltd. This significant moment symbolises the shared vision of Synaura Biotech and its partners within the HMO sector, representing a firm stride forward on their future development path.

Synaura Exhibition Stand

At the exhibition stand, visitors demonstrated considerable enthusiasm for Synaura's comprehensive solutions, pausing frequently to enquire.

FIC2024 represents another significant milestone in Synaura Biotech's development journey. With the successful conclusion of the exhibition, Synaura Biotech will achieve further innovations in the HMO field, making greater contributions to global nutrition and health initiatives.